The New England journal of medicine
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Sara M Tolaney, Zefei Jiang, Qingyuan Zhang, Romualdo Barroso-Sousa, Yeon Hee Park, Mothaffar F Rimawi, Cristina Saura, Andreas Schneeweiss, Masakazu Toi, Yee Soo Chae, Yasemin Kemal, Mukesh Chaudhari, Mehmet A N Şendur, Toshinari Yamashita, Monica Casalnuovo
Published: 202510.1056/NEJMoa2508668
Abstract
BACKGROUND: Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer. The efficacy and safety of trastuzumab deruxtecan in patients wit…
Preview only. Read the full abstract at the source